The immunogenicity of chimeric antibodies
. J Exp Med 1989:170(6):2153-2157.
For example, chimeric antibodies
chCE7 targeting L1CAM that were developed in the 1980s  bind the CE7 epitope of L1 and are internalized by neuroblastoma and renal carcinoma cells .
are composed of murine variable regions fused onto human constant regions.
Although chimeric antibodies
are currently approved by the US FDA for clinical use, most of the therapeutic antibodies currently in use are humanized or fully human.
Using recombinant DNA technology, chimeric antibodies
, which consist of human constant domains with murine variable regions (e.g., rituximab, Rituxan[R]; 2006) and humanized antibodies, where mainly the complementarity determining regions (CDRs) are of nonhuman origin (e.g., daclizumab, Zinbryta[R]; 2003), can be generated.
Our observation was in agreement with the previous 2 reports of chimeric antibodies
with analogous specificity, albeit with different reactivity, vs those of the original antibody, because of immunoglobulin subclass (21, 22).
Antibodies to chimeric antibodies
(HACA) may be directed against a wide variety of epitopes in both the antigen combining site or framework epitopes in both the constant and variable regions of the immunoglobulin molecule.
 presented the treatment of a mouse model of chimeric antibodies
which blocked the intracellular PRL-3 protein.
In addition, functional single chain antibodies, antibody fragments and chimeric antibodies
may also be produced.
Wesolowski, "High-level expression of chimeric antibodies
using adapted cDNA variable region cassettes," Journal of Immunological Methods, vol.
The challenge of this method lies in being able to distinguish the tryptic peptides from the vast repertoire of endogenous immunoglobulins present in human serum, which is easier for chimeric antibodies
such as infliximab but can be more challenging for fully human antibodies such as adalimumab.